title: The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism.
abstract: BACKGROUND
  The relationship between subclinical hypothyroidism (SH) and cardiovascular disease (CVD) is still under debate. The purpose of the present study was to evaluate plasma total homocysteine (tHcy), high sensitive C-reactive protein (hsCRP), small dense low-density lipoprotein (sdLDL), L-arginine and asymmetric dimethylarginine (ADMA) concentrations and their relationship to nitric oxide (NO) production, measured as plasma nitrite-plus-nitrate (NO(x)) concentration, in patients with SH before and after thyroxine replacement therapy and compared with control group values.
  
  
  METHODS
  Eighty-four women with SH and 33 healthy women as controls matched to the patient group for sex, age and body mass index (BMI), were enrolled in this study. Lipoprotein profile, tHcy, hsCRP, sdLDL, ADMA, L-arginine and NO(x) were measured in pre- and post-treatment blood samples.
  
  
  RESULTS
  The pretreatment total cholesterol (TC), LDL-C, hsCRP, ADMA and L-arginine levels were significantly higher and NO(x) levels were lower than in the control group. After treatment, hsCRP, ADMA and L-arginine levels were significantly reduced and sdLDL and NO(x) levels were significantly increased.
  
  
  CONCLUSIONS
  The present study demonstrated an elevation of hsCRP and ADMA plasma levels of patients with SH associated with a reduction in NO production, which may contribute to some cardiovascular alterations. The elevated ADMA and hsCRP levels were reduced after thyroxine replacement. Also the sdLDL levels of SH patients were found to be lower than the control group values whereas TC and LDL were elevated. Even though we found an elevation in sdLDL levels after treatment, those values were still not higher than in the control group.
authors.affiliation: Department of Emergency Medicine, Gulhane School of Medicine, Etlik, Ankara, Turkey.
authors.forename: Omer
authors.initials: O
authors.lastname: Ozcan
authors.forename: Erdinc
authors.initials: E
authors.lastname: Cakir
authors.forename: Halil
authors.initials: H
authors.lastname: Yaman
authors.forename: Emin Ozgur
authors.initials: EO
authors.lastname: Akgul
authors.forename: Kivilcim
authors.initials: K
authors.lastname: Erturk
authors.forename: Zeynel
authors.initials: Z
authors.lastname: Beyhan
authors.forename: Cumhur
authors.initials: C
authors.lastname: Bilgi
authors.forename: Mehmet Kemal
authors.initials: MK
authors.lastname: Erbil
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology*; D002784:Cholesterol / Q000097:blood; D004791:Enzyme Inhibitors / Q000097:blood*; D005260:Female; D006710:Homocysteine / Q000097:blood; D020249:Hormone Replacement Therapy; D006801:Humans; D007037:Hypothyroidism / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008875:Middle Aged; D009569:Nitric Oxide / Q000096:biosynthesis; D012307:Risk Factors; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood / Q000627:therapeutic use*; D014284:Triiodothyronine / Q000097:blood
chemical_list: D015415:Biomarkers; D004791:Enzyme Inhibitors; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D014284:Triiodothyronine; D006710:Homocysteine; D009569:Nitric Oxide; C018524:N,N-dimethylarginine; D013972:Thyrotropin; D002097:C-Reactive Protein; D001120:Arginine; D002784:Cholesterol; D013974:Thyroxine